Oxydevit, oral solution 0.0009%, 5ml

Composition

Active ingredient:

alfacalcidol 9 mcg.

Pharmacological action

Regulator of calcium and phosphorus metabolism,1α-hydroxyvitamin D3. Causes an increase in the absorption of calcium and phosphorus in the intestine, an increase in their reabsorption in the kidneys; regulates bone mineralization.

Pharmacokinetics

After oral use, alfacalcidol is rapidly absorbed from the gastrointestinal tract. Tmax of the Active ingredient in blood plasma is from 8 to 18 hours

. Alfacalcidol is metabolized in the liver to form the main active metabolite of calcitriol (1α,25-dihydroxyvitamin D3). A smaller part of the Active ingredient is metabolized in bone tissue.

Indications

Osteodystrophy (including chronic renal failure), hypoparathyroidism and pseudohypoparathyroidism, rickets and osteomalacia of various origins, osteoporosis (including postmenopausal, senile, steroid), renal acidosis, Fanconi syndrome (hereditary renal acidosis with nephrocalcinosis, late rickets and adiposogenital dystrophy).

Use during pregnancy and lactation

Oxydevit is contraindicated during pregnancy and lactation.

Contraindications

Hypercalcemia, hyperphosphatemia (except for hyperphosphatemia in hyperparathyroidism), hypermagnesemia, vitamin D intoxication, lactation (breastfeeding), hypersensitivity to alfacalcidol.

Side effects

An allergic reaction is possible, and in case of overdose, hypercalcemia, which usually passes 2-3 days after discontinuation of the drug. The drug is re-prescribed in smaller doses.

How to take, course of use and dosage

Apply inside regardless of the intake of food.

Children with rickets-like diseases are prescribed 0.0005-0.003 mg/day. depending on age and body weight for 2-3 months, sometimes up to 1 year. For rickets,0.001 mg/day is used daily for 10 days. Spend 3 courses with a break between them in 2 weeks.

In case of chronic renal failure, children undergoing hemodialysis (a method of blood purification) are prescribed 0.001 mg/day to stop (remove) osteodystrophy. with simultaneous use of vitamin D2 for 2000 IU daily for a long time.

Adults with chronic renal failure who are on hemodialysis are prescribed 0.001-0.002 mg / day daily or every other day, followed by a dose reduction to 0.0005 mg, depending on the normalization of blood calcium content and alkaline phosphatase activity.

Courses for 2-3 months are recommended to be repeated 2-3 times a year.

In case of chronic renal failure, preliminary correction of hyperphosphatemia (normalization of elevated phosphorus content in the blood) is required. Patients after kidney transplantation are prescribed 0.00025-0.001 mg/day daily or every other day for preventive purposes.

In cases of bone pathology (osteoporosis, osteomalacia) of various origins, the drug is used at 0.0005-0.003 mg / day. for a long time (from 2-3 months to 1 year or more). Therapy with oxidevit should be carried out under constant monitoring of the content of calcium and phosphorus in the blood, as well as the activity of alkaline phosphatase (with chronic renal failure, weekly monitoring).

Special instructions

Use with caution in patients with an increased risk of hypercalcemia, especially in urolithiasis.

During treatment, you should regularly monitor the level of calcium in blood plasma and urine, monitor the development of the therapeutic effect and, if necessary, adjust the dose of alfacalcidol to avoid the development of hypercalcemia and hypercalciuria.

Unlike natural vitamin D, alfacalcidol is not metabolized in the kidneys. There are reports of the effectiveness of alfacalcidol in secondary hyperparathyroidism caused by renal failure.

Form of production

Solution for oral use

Storage conditions

In a dark place, at room temperature

Shelf life

2 years

Active ingredient

Alfacalcidol

Conditions of release from pharmacies

By prescription

Dosage form

oral solution